OTR Acquisition Corp.
Status: Deal Closed
U=S+W/2
W=S@11.5
IPO Proceeds, $M | $104.77M |
---|---|
IPO Date | Nov 17, 2020 |
CEO | Nicholas J. Singer |
Left Lead | Maxim |
IPO Cash in Trust | 102.2% |
SPAC Tenor | 18 months |
IPO Sector |
General
Not specified |
IPO Geography | Global |
Target Company | Comera Life Sciences |
Deal Announced | Jan 31, 2022 |
Deal Size, $M | $151.30M |
Deal Sector | Healthcare |
Deal Geography | US/Canada |
SEC Filings | www.sec.gov |
Approval Vote | May 10, 2022 |
Amendment Vote | TBD |
Closing Date | May 19, 2022 |
Formerly OTRA
CMRA
CMRAW
Price | $0.00 |
---|---|
Last closing price | $0.00 |
H/L, today | $0.00 / $0.00 |
H/L, 52-week | $0.22 / $2.17 |
Volume, today | 200 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on OTR Acquisition Corp.:
- Structure and cap table
- 6 directors & officers
- 25 filings and events
- 2 underwriters
- 1 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Nicholas J. Singer | 41 | CEO and Chairman |
Douglas B. Anderson | 51 | CFO and Director |
David Neithardt | 51 | Director |
Glenn Gray | 66 | Director |
Nadav Besner | 41 | Director |
Mr. Amir Rozwadoski | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Maxim | BR | 8,052,500 | units |
EarlyBirdCapital | 1,947,500 | ||
10,000,000 | units | ||
Up-Front UW fee | 1.25 | % | |
Deferred UW fee |
3.24 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.